This may include, but is not limite d to, redaction of the following: 

•Title: A Single-Sequence, Open-Label, 2-Period, Crossover Trial to Evaluate the Effect of the
Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral
TAK-906 in Healthy Adult Subjects.
Study ID: [REMOVED]
Protocol Approve Date: 25 May 2017
Certain information  within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable 
information 
or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
A Single- Sequence, Open -Label, 2- Period, Crossover Trial to Evaluate the Effect of the 
Potent CYP3A4 Inhibitor Itraconazole on the Single -Dose Pharmacokinetics of Oral 
TAK -906 in Healthy Adult Subjects.
Study Identifier : TAK-906-1003
Compound: TAK-906 maleate
Date: 25 May 2017 Version/Amendment 
Number:01
Amendment History: 
Date Amendment NumberAmendment Type (for regional 
European purposes only) Region
21 March 2017 Initial version Not applicable Global
25May 2017 01 Nonsubstantial Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or d isclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
TAK -906
Study No. TAK -906-1003 Page 2of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIALTABLE OF CONTENTS
1.0 TRIAL SUMMARY ........................................................................................................ 6
1.1 Protocol  Amendment No. 01 Summary  of Changes ................................................... 8
2.0 TRIAL SCHEMATIC ..................................................................................................... 9
3.0 SCHEDULE OF TRIAL PR OCEDURES ...................................................................... 10
4.0 INTRODUCTION ......................................................................................................... 13
4.1 Backgrou nd............................................................................................................. 13
4.2 Rationale for the Proposed Trial ............................................................................... 14
4.3 Benefit/Risk Profile .................................................................................................14
5.0 TRIAL OBJECTIVES AND ENDPOINTS ................................................................... 15
5.1 Object ives................................................................................................................ 15
5.1.1 Primary Object ive............................................................................................ 15
5.1.2 Secondary  Object ive........................................................................................ 15
5.1.3 Exploratory  Objectives .................................................................................... 15
5.2 Endpoints ................................................................................................................. 15
5.2.1 Primary Endpo int(s)......................................................................................... 15
5.2.2 Safety Endpo ints.............................................................................................. 15
5.2.3 Exploratory  Endpo ints..................................................................................... 15
6.0 TRIAL DESIGN AND DES CRIPTION ........................................................................ 17
6.1 Trial Design ............................................................................................................. 17
6.2 Rationale for Tri al Design, Dose, and Endpoints ...................................................... 17
6.2.1 Rationale of Tri al Desi gn and Dose .................................................................. 17
6.2.2 Rationale for Endpoints ................................................................................... 18
6.2.3 Critical Procedures Based on Trial Object ives: Timing of Procedures .............. 18
6.3 Trial Beginning and End/Complet ion....................................................................... 19
6.3.1 Definit ion of Beginning o f the Tri al.................................................................19
6.3.2 Definit ion of End of the Trial ........................................................................... 19
6.3.3 Definit ion of Trial Discont inuat ion.................................................................. 19
6.3.4 Criteria for Premature Terminat ion or Suspension of the Trial ......................... 19
7.0 SELECTION AND DISCONTINUATION/WITH DRAWAL OF SUBJECTS .............. 20
7.1 Inclusio n Cri teria..................................................................................................... 20
7.2 Exclusio n Cri teria.................................................................................................... 21
7.3 Excluded Medicat ions, Supplements, D ietary Products ............................................ 23
7.4 Diet, Fl uid, Act ivity.................................................................................................23
7.4.1 Diet and Fluid .................................................................................................. 23
TAK -906
Study No. TAK -906-1003 Page 3of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIAL7.4.2 Activity........................................................................................................... 24
7.5 Criteria f or Di scontinuati on or Wi thdrawal  of a Subject ........................................... 24
7.6 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 25
7.7 Subject Replacement ................................................................................................ 25
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT ...................................................... 26
8.1 Clinical Trial Drug ................................................................................................... 26
8.1.1 Clinical Trial Drug Labeling ............................................................................ 26
8.1.2 Clinical Trial Drug Inventory  and Storage ....................................................... 26
8.1.3 Clinical Trial Drug Blinding ............................................................................ 26
8.1.4 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................. 26
8.1.5 Ancillary  Supplies ........................................................................................... 26
9.0 TRIAL PROCEDURES .................................................................................................27
9.1 Administrative Procedures ....................................................................................... 27
9.1.1 Inform ed Consent Procedure ............................................................................ 27
9.1.2 Assignment of Screening Numbers .................................................................. 27
9.1.3 Inclusio n and Exclusio n Cri teria...................................................................... 27
9.1.4 Medical History /Dem ographics ....................................................................... 27
9.1.5 Prior and Concomi tant Medicat ion Review ...................................................... 27
9.1.6 Physical Examinat ions..................................................................................... 27
9.1.7 Vital Sign Measurements ................................................................................. 27
9.1.8 Height and Wei ght........................................................................................... 28
9.1.9 BMI ................................................................................................................. 28
9.1.10 12-Lead ECG ................................................................................................... 28
9.1.11 AE Monitoring ................................................................................................ 29
9.2 Laboratory  Procedures and Assessments .................................................................. 29
9.3 PK and PGx Samples ............................................................................................... 31
9.3.1 PK Evaluat ions................................................................................................ 31
9.3.2 PGx Measurements .......................................................................................... 32
9.4 Trial Drug Administrati on........................................................................................ 33
9.5 Confinement ............................................................................................................ 33
10.0 ADVERSE EVENTS .................................................................................................... 34
10.1 Definitions and El ements of AEs ............................................................................. 34
10.1.1 SAEs ............................................................................................................... 36
10.1.2 Speci al Interest AEs ......................................................................................... 37
10.2 AE Procedures ......................................................................................................... 37
TAK -906
Study No. TAK -906-1003 Page 4of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIAL10.2.1 Assigning Severit y/Intensit y of AEs ................................................................ 37
10.2.2 Assigning Causalit y of AEs ............................................................................. 37
10.2.3 Assigning Relat ionship to Trial Procedures ...................................................... 38
10.2.4 Start Date ......................................................................................................... 38
10.2.5 Stop Date ......................................................................................................... 38
10.2.6 Frequency ........................................................................................................ 38
10.2.7 Action Concerning Trial Drug ......................................................................... 38
10.2.8 Outcom e.......................................................................................................... 38
10.2.9 Collect ion and Reporti ng of AEs, SAEs, Special Interest AEs, and Abnormal 
LFTs ................................................................................................................ 39
10.2.10 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties...41
11.0 STATISTICAL METHODS .......................................................................................... 42
11.1 Statistical and Analyt ical Plans ................................................................................ 42
11.1.1 Analysis Sets ................................................................................................... 42
11.1.2 Analysis of Demographics and Other Baseline Characterist ics......................... 42
11.1.3 PK Analysis ..................................................................................................... 42
11.1.4 Safety Analysis ................................................................................................ 43
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 44
11.3 Determinat ion of Sample Size .................................................................................. 44
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 45
12.1 Trial-Site Moni toring Visi ts..................................................................................... 45
12.2 Protocol  Deviat ions.................................................................................................. 45
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 45
13.0 ETHICAL ASPECTS OF T HE TRIAL ......................................................................... 46
13.1 IRB and/or IEC Approval ........................................................................................ 46
13.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 47
13.3 Subject Confidentialit y............................................................................................ 48
13.4 Publicat ion, Di sclosure, and Clinical Trial Registr ation Policy .................................48
13.4.1 Publicat ion and Disclosure ............................................................................... 48
13.4.2 Clinical Trial Registration ................................................................................ 49
13.4.3 Clinical Trial Result s Disclosure ...................................................................... 49
13.5 Insurance and Co mpensation for Injury .................................................................... 49
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......................................... 50
14.1 Administrative Informat ion...................................................................................... 50
14.1.1 Trial Contact Information ................................................................................ 50
15.0 INVESTIGATOR AGREEME NT................................................................................. 51
TAK -906
Study No. TAK -906-1003 Page 5of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIAL15.1 Trial-Related Responsibilit ies.................................................................................. 52
15.2 List of Abbreviat ions............................................................................................... 53
16.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 55
16.1 eCRFs ...................................................................................................................... 55
16.2 Record Retention ..................................................................................................... 55
17.0 REFERENCES .............................................................................................................. 57
18.0 APPENDI CES............................................................................................................... 58
LIST OF IN -TEXT TABLES
Table 7.a Excluded Medicat ions, Supplements, and Dietary  Products ................................ 23
Table 9.a Primary Specimen Collections ........................................................................... 31
Table 10.a Takeda Medically Significant AE List ................................................................ 37
LIST OF APPENDICES
Appendix A Detailed Descript ion of Amendments to Text ..................................................... 59
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 63
Appendix C Elements of the Subject Informed Consent ......................................................... 65
Appendix D Invest igator Consent to Use of Personal Informat ion.......................................... 68
Appendix E Pregnancy and Contraception ............................................................................. 69
TAK -906
Study No. TAK -906-1003 Page 6of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIAL1.0 TRIAL SUMMARY
Name of Sponsor:
Millennium Pharmaceuticals, Inc 
40 Landsdowne Street
Camb ridge, MA 02139Compound:
TAK -906 maleate
Study Number: 
TAK -906-1003Phase: 1
Protocol Title: A Single -Sequence, Open -Label, 2 -Period, Crossover Trial to Evaluate the Effect of the Potent 
Cytochrome P -450 3A4CYP3A4 Inhibitor Itraconazole on the Single -Dose Pharmacokinetics of Oral TAK -906 in 
Healthy  Adult Subjects.
Trial Design:
This is a phase 1, single -sequence, open -label, 2 -period crossover trial in approximately 12 healthy male and female 
(nonchildbearing -potential) subjects. The trial is designed to investigate the effect of a potent cytochrome P -450 
(CYP) 3A4 inhibitor (itraconazole) on the pharmacokinetics (PK) of TAK -906. 
The trial will include a Screening Visit, a Period 1 (Day s 1 to 3), followed by a minimum of a 4 -day washout from the 
time of TAK -906 maleate dose, a Period 2 (Days 1 to 6), and a Follow -up Visit. 
On Day  1 of Period 1, eligible subjects will be enrolled into the trial and will receive a single oral (PO) do se of 
TAK -906 maleate 25 mg. On Days 1 to 5, inclusive, of Period 2, subjects will receive itraconazole 200 mg once daily 
(QD) PO solution. Following after an overnight fast of at least 8 hours, a single PO dose of TAK -906 maleate 25 mg 
will be administere d 1 hour after the itraconazole dose on Day 4 of Period 2. Both doses of TAK -906 maleate will be 
administered after an overnight fast of at least 8 hours as food reduces its bioavailability by approximately 40%.
Blood samples for assessment of TAK -906 concentrations will be collected from predose to 48 hours after each dose 
of TAK -906 maleate. 
Safety will be assessed by monitoring for adverse events, vital signs, electrocardiograms ( ECGs) , clinical laboratory 
results, and physical examinations thro ughout each dosing period.
After completion of the trial (or following subject withdrawal), all subjects will return for a Follow -up V isit 10 to 14 
days after their last dose of TAK -906 maleate.
Primary Objective:
To evaluate the effect of the potent CYP3A4 inhibitor itraconazole on the single -dose PK of PO TAK -906 maleate.
Secondary Objectives:
To evaluate the safety and tolerability of a single PO dose of TAK -906 maleate in the presence and absence of a potent 
CYP3A4 inhibitor.
Subject Population: Healt hy male and female ( nonchildbearing ) subjects. 
Number of Subjects:
12Number of Sites:
1 site
Dose Levels:
TAK -906 maleate 25 mg QD
Itraconazole 200 mg QDRoute of Administration:
TAK -906 maleate: PO
Itraconazole: PO
Duration of Treatment:
2 QD TAK -906 maleate doses 
5 QD itraconazole dosesPeriod of Evaluation:
Approximately 7 to 8 weeks
TAK -906
Study No. TAK -906-1003 Page 7of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIALMain Criteria for Inclusion:
Healthy  male and female (nonchildbearing -potential) subjects who are aged 18 to 55 years, inclusive, with a body 
mass index (BMI) between 18 to 30 kg/m2, and a body weight >50 kg.
Main Criteria for Exclusion:
Subjects who have a history of clinically significant endocrine, gastrointestinal (GI) (including motility disorder and 
intestinal obstruction), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or 
major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial.
Main Criteria for Evaluation and Analyses:
Plasma PK paramet ers (maximum observed concentration [C max], area under the concentration -time curve from time 0 
to time of the last quantifiable concentration [AUC last], and area under the concentration -time curve from time 0 to 
infinity , calculated using the observed val ue of the last quantifiable concentration [AUC ∞]) for TAK -906 will be 
derived on Day 1 of Period 1 and on Day 4 of Period 2.
Safety endpoints: 
Safety and tolerability will be assessed through physical examinations, ECGs, vital signs, and clinical laboratory 
results, as well as collection of spontaneous adverse events (AEs).
Statistical Considerations:
The PK parameters of TAK -906 (and metabolites, if possible) will be summarized by regimen using descriptive 
statistics. Linear and semilogarithmic p lots of the mean and individual concentration -time curves will be provided. 
Individual plasma concentration and PK parameter data will be presented in the data listing. 
For evaluation of potential effect of itraconazole on TAK -906 PK, paired t -tests and a ssociated 90% confidence 
intervals (CIs) will be determined on the natural logarithms of C maxand AUCs to assess the exposure between 
regimens (TAK -906 maleate alone and TAK -906 maleate with itraconazole). The geometric mean of the relative 
bioavailability of the TAK-906 maleate with itraconazole regimen relative to the TAK -906 maleate alone regimen and 
the associated 90% CIswill be determined by exponentiating the appropriate estimates for the difference between 
regimens in the log-transformed parameters.
Sample Size Justification:
Approximately 12 subjects will be enrolled in this trial. The sample size justification is based on an acceptance range 
of 50% to 200% and assumes that the intrasubject percent coefficient of variation (%CV) for AUC lastand C maxof 
TAK -906 will not exceed 25%. This sample size will provide 80% power to conclude plasma concentration of 
TAK -906 will not increase more than 2-fold in the presence of itraconazole.
Subjects who drop out for nonsafety reasons may be replaced at the d iscretion of the investigator in consultation with 
the sponsor. Subjects who drop out for safety reasons will not be replaced.
TAK -906
Study No. TAK -906-1003 Page 8of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIAL1.1 Protocol Amendment No. 01 Summary of Changes
Rationale for Amendment 01
This document describes the changes in reference to the protocol  incorporati ng Amendment 
No.01.
The primary  reason for thi s amendment is to add addit ional laboratory  and screening procedures . 
Num erous cl arificat ion and administrative changes have also been made.
Minor grammat ical and editorial changes are incl uded for clarificat ion purposes only. For specific 
descript ionsoftextchanges and where the changes are located, seeAppendix A. 
Changes in Amendment 01:
1. Added addi tional serum  β-human chorionic gonadotropin (hCG) tests.
2.Clarified use of follicle st imulat ing hormone (FSH) test.
3.Extended the morning dosing time range for the TAK -906.
4.Aligned timing and procedures for collect ion of AE throughout document.
5.Removed data collection using digital wearable devices.
6.Clarified birth control  requi rements for female partners of male subjects.
7.Updated predose restrict ion for xanthine and/or caffeine use. 
8.Added urine cotinine as part of drug screen.
9.Corrected ty pographi cal errors, punctuati on, grammar, and formatting.
TAK -906
Study No. TAK -906-1003 Page 9of 70
Protocol Incorporating Amendment No. 01 25May 2017
CONFIDENTIAL2.0 TRIAL SCHEMATIC

TAK -906
Study No. TAK -906-1003 Page 10of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL3.0 SCHEDULE OF TRIAL PR OCEDURES 
Screening Period 1 (a) Period 2Follow -up/Early 
Termination
Procedures/Assessments Day -28to-2Day Day10-14days after 
last dose of 
TAK -906
-1Predose
(Day 1) 1 2 3 1 2 3 4 5 6
Administrative Procedures
Informed consent X
Inclusion/ exclusion criteria X X X
Medical history/demographics X
Prior and concomitant medication review ------------------------------------ Continuous Monitoring -----------------------------
Clinic Procedures/Assessments
Full physical examination X X (b) X
Height X
Weight X
BMI X
12-Lead ECG X X(c) X(c) X X(c) X X
Semirecumbent vital signs (heart rate [HR], systolic 
blood pressure and diastolic blood pressure X X(d) X(d) X X X(d) X X
Vital signs (respiratory rate, oral [at the floor of the 
mouth]/tympanic temperature) rateX X X X X X X X
TAK -906 administration X X
Itraconazole administration (e) X X X X X
AE m onitoring --------- Continuous Monitoring --------
TAK -906
Study No. TAK -906-1003 Page 11of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALScreening Period 1 (a) Period 2Follow -up/Early 
Termination
Procedures/Assessments Day -28to-2Day Day10-14days after 
last dose of 
TAK -906
-1Predose
(Day 1) 1 2 3 1 2 3 4 5 6
Laboratory Procedures/Assessments
Hematology X X (b) X (b) X X
Urinalysis X X (b) X (b) X X
Chemistry X X (b) X (b) X X
Serum follicle stimulating hormone (FSH) X
β-human chorionic gonadotropin (hCG) X X X
Urine drug screen X X X
Urine alcohol test/alcohol breath test (f) X X X
Hepatitis screen X
Human immunodeficiency virus ( HIV) X
Pharmacokinetics Evaluations
PGx DNA collection X
PGx RNA collection X
CCI
CCI
TAK -906
Study No. TAK -906-1003 Page 12of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALScreening Period 1 (a) Period 2Follow -up/Early 
Termination
Procedures/Assessments Day -28to-2Day Day10-14days after 
last dose of 
TAK -906
-1Predose
(Day 1) 1 2 3 1 2 3 4 5 6
Other
Confinement X-------------- X X------------ X
Meals fasting (i) X X X
(a) There will be a minimum 4 day washout between Periods 1 and 2, starting from administration of TAK -906 maleate on Day 1 of Period 1.
(b) Day 1 predose assessment may be done within approximately 24 hours prior to trial drug administration.
(c) Triplicate measurements to be conducted at 0 (predose), 1, 2, 4, 8 and 48 hours postdose (times relative to TAK -906 maleate dose).
(d) Measured at 0 (predose), 1, 2, 4, 8 and 48 hours postdose (times relative to TAK -906 maleate dose).
(e) Itraconazole will be administered once daily at the same time each day and 1 hour prior to TAK -906 maleate on Day 4.
(f) An alcohol breath test may be performed at the discretion of the investigator.
(g) 
 
(h)  
(i) Subjects will fast overnight at least 8 hour before dose of TAK -906 maleate on Day 1 of Period 1 and at least 8 hours before itraconazole and TAK -906 maleate doses on Day 4 of 
Period 2.
CCI
CCI
CCI
CCI
TAK -906
Study No. TAK -906-1003 Page 13of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
The intended indicat ion for TAK -906 m aleate i s to treat pati ents wi th gastroparesi s, a di sorder of 
the stom ach characteri zed by  delayed gastri c emptying in the absence of mechanical obstruction. 
Symptom s are chronic with episodic symptom exacerbat ion [1]. These symptoms may include 
nausea, vo miting, early satiety , abdominal  pain, and postprandial fullness. The prevalence of 
gastroparesi s in the United States is 24.2 per 100,000 [2]. In cases o f chronic gastroparesis, 
diabetic (29%), postsurgical (13%), and idiopathic (36%) etio logies comprise the majorit y of cases 
in the tertiary referral setting [3]. Currently in the United States, there exists a large unmet medica l 
need because there are no approved therapies for the chronic treatment of diabet ic gastroparesi s. 
Validated targets for ga stroparesis are the D 2and D 3dopamine (DA) receptors. The D 2 receptor 
antagonist metoclopramide is indicated for the short -term treatm ent of acute and recurrent diabet ic 
gastroparesi s and has been limited in dose and duration of treatment by  well -docum ented 
toxicities, the m ost notabl e of which are a category of mo vement disorders known as 
extrapy ramidal  symptoms (EPS) [4]. EPS are caused by the blockade of DA D 2receptors in the 
dorsal  striatum  and thus are potential sid e effects of all centrally- penetrant drugs that share this 
mechanism o f action, parti cularly  select ive DA D 2antagonists. Of greatest concern is tardive 
dyskinesia, a severe and often irreversible EPS. The risk of developing tardive dyskinesia 
increases wi th dose l evel and durati on of  treatm ent and as such, the United States package insert 
includes a black box warning regarding the chronic use of me toclopramide for l onger than 
12weeks.
Dom peridone is a peri pherally -acting DA D 2/D3receptor antagonist marke ted for use as an 
anti-emet ic and prokinet ic agent in a number of countries worldwide, although not in the United 
States due to its cardiovascular safet y profile which includes a risk for drug -induced long QT 
syndro me, torsades de pointes, and sudden cardi ac death [5].
DA receptor antagonists are effect ive in the treatment of delayed gastric empt ying and 
gastroparesi s symptom s because of the role of D 2and D 3receptors in the upper gastrointestinal 
(GI) tract and in the area postrem a which controls vomit ing [6-8].Both of these areas are outside 
of the bl ood brain barrier. Therefore, a peripherally -selective D 2/D3antagonist could achieve the 
desired efficacy  without the undesired central  nervous sy stem  (CNS )effects [9,10] . TAK -906 i s a 
peripherally  select ive (ie, very limited penetration of the blood brain barrier) dopamine D 2/D3
receptor antagonist. It demonstrated suitable pharmacokinet ics (PK)and pharmacodynamic (PD) 
activit y in a phase 1 trial in healt hy vo lunteers wi thout the CNS liabilit ies of m etocl opramide or 
cardi ac liabilit ies associated with do mper idone. Therefore TAK -906 i s expected to reduce nausea 
and vo miting, and to have prokinetic effects, without the side effects which restrict the use of other 
D2/D3antagonist. 
TAK -906 shows rapid absorption. Half -life following a single oral (PO) dose averaged 
approxima tely 4hours when administered in the fasted state. Food had a si gnificant impact on 
reducing the exposure to TAK-906.
In conclusio n, TAK -906 maleate is a promising therapeutic for the treatment of gastroparesis.
TAK -906
Study No. TAK -906-1003 Page 14of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALPlease refer to the TAK -906 Invest igator’s Brochure for com plete inform ation on the 
investigat ional product and the most recent itraconazole product insert for the appropriate region.
4.2 Rationale for the Proposed Trial
TAK -906 has been shown to undergo oxidative metabolism in human liver microsomes and hence 
involvement of cy tochrome P- 450 (CYP) enzymes is possible (2C8, 3A4 and 1A2). Thus, this 
phase 1, single -sequence, open -label, 2-period crossover tri al is designed to invest igate the effect 
of a potent CYP3A4 inhibitor (itraconazole) on the PK of a single PO dose of TAK -906 m aleate 
25mgin healthy men and wom en.
4.3 Benefit/Risk Profile
As thi s is a tri al in heal thy subjects, there is no expected clinical benefit to the trial participants. 
Potenti al risks are based on clinical findings, the mechanism of act ion, and nonclinical findings. 
Also, there is minimal risk associated with study  procedures including scheduled, periodic 
phlebotomy  (limi ted to <500 mL), and noninvasive procedures including vital sign assessments 
and electrocardiograms (ECGs). The principal mit igation for these ri sks include appropri ate 
select ion of the study  popul ations, the clinical research unit (CRU) study  setting permitting close 
monitoring and rapid inst itution of appropriate care as needed, appropriate specified monitoring 
procedures, and utilizat ion of experienced staff trained in study procedures. Overall, the 
risk:benefit profile is considered appropriate for this trial .
TAK -906
Study No. TAK -906-1003 Page 15of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL5.0 TRIAL OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objective
The primary  object ive of the trial is to evaluate the effe ct of the potent CYP3A4 inhibitor 
itraconazo le on the single -dose PK of PO TAK -906 maleate.
5.1.2 Secondary Objective
The secondary  objective of the tri al to eval uate the safet y and tol erabili ty of single PO dose of 
TAK -906 m aleate in the presence and absence of a potent CYP3A4 inhibitor.
5.1.3 Exploratory Objectives
Exploratory  endpo ints of this tri al include: 
5.2 Endpoints
5.2.1 Primary Endpoint(s)
The primary endpo ints of the trial are the following plasma PK parameters for TAK -906 on Days 1 
and 4:
Maximum observed concentration ( Cmax).
Area under the concentration -time curve from t ime 0 to time of the last quantifiable
concentration (AUC last).
Area under the concentration -time curve fro m time 0 to infinit y, calculated using the observed
value of the last quantifiable concentration (AUC ∞).
5.2.2 Safety Endpoints 
Safety endpo ints include the fo llowing: 
Safety and tol erabilit ywill be assessed through physical examinat ions, ECGs, vital signs,
clinical laboratory  resul ts, and collect ion of spontaneous adverse events ( AEs).
5.2.3 Exploratory Endpoints
Exploratory  endpo ints will be assessed through the fo llowing param eters: 
CCI
CCI
TAK -906
Study No. TAK -906-1003 Page 16of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL
CCI
TAK -906
Study No. TAK -906-1003 Page 17of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL6.0 TRIAL DESIGN AND DES CRIPTION
6.1 Trial Design 
This is a phase 1, single -sequence, open -label, 2-period crossover tri al in approximately 
12healt hy male and female (nonchildbearing -potent ial) subjects. The trial is designed to 
investigate the effect of a potent CYP3A4 inhibitor (itraconazole) on the PK of TAK-906.
The tri al will include a Screening Visit, a Period 1 (Day s 1 to 3), fo llowed by  a minimum of a 
4-day washout from the time of TAK -906 maleate dose, a Period 2 (Days 1 to 6), and a Follow -up 
Visit. 
On Day  1 of Period 1, eligible subjects will be enrolled into the trial and will receive a single PO 
dose of TAK -906 m aleate 25 m g. On Days 1 to 5, inclusive, of Period 2, subjects will receive 
itraconazo le 200 mg once daily ( QD) PO sol ution. Foll owing after an overnight fast of at least 8 
hours, a single PO dose of TAK- 906 m aleate 25 mg will be administered 1 hour after the 
itraconazo le dose on Day 4 of Period 2. Both doses of TAK -906 maleate will be administered after 
an overnig ht fast of at least 8 hours as food reduces its bioavailabilit y by approximately 40%.
Itraconazole will be administered to subjects under clinic supervisio n on an outpatient basis on the 
morning o f Days 1 to 3 of Period 2 and during confinement on Day s 4 to 5 of Peri od 2. 
Blood sam ples f or assessment of TAK -906 concentrations will be collected from predose to 
48hours after each dose of TAK -906 maleate. Samples may be assayed for TAK -906 m etabo lites 
if deemed necessary . Urine samples will be collected thro ugh 48 hours and may be assayed for 
TAK -906 concentrations and metabo lites if deemed necessary  for the interpretati on of  data.
Who le blood sam ples for deoxy ribonucleic acid (DNA) pharmacogeno mics (PGx) analysis and 
ribonucleic acid (RNA) iso lation will be collected predose on Day  1 of Trial Peri od 1.
Safety will be assessed by monitoring for adverse events, vital signs, ECGs, clinical laboratory  
resul ts, and physical examinat ions throughout each dosing period.
After complet ion of the trial (or following su bject wi thdrawal), all subjects will return for a 
Follow-up V isit 10 to 14 days after their last dose of TAK -906 m aleate.
6.2 Rationale for Trial Design, Dose, and Endpoints
6.2.1 Rationale of Trial Design and Dose
Itraconazole has been chosen as it is recommended b y the Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) as a suitable potent CYP3A4 inhibitor for use in 
drug-drug interaction (DDI) studies. CYP3A4 is the most common CYP enzyme responsible for 
oxidative metabo lism, and hence the effe ct of itraconazol e, a potent CYP3A4 inhibitor, on 
TAK -906 PK will be investigated. This type of DDI trial is typically conducted in healt hy subjects. 
A single -sequence tri al has been chosen to enable assessment of the PK of a single PO dose of 
TAK -906 m aleate in the presence and absence of mult iple doses of itraconazole.
TAK -906
Study No. TAK -906-1003 Page 18of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALA single PO dose of TAK -906 maleate 25mg has been chosen as it is expected to be clinically  
relevant ,ie, 25 mg is expected to provide maximal D 2receptor occupancy at a mean C maxof 
approximately  11ng/mL. In addit ion, thi s dose i s well bel ow the m aximum  single dose (300 mg) 
that has been invest igated to date that was shown to be well tolerated in healt hy subjects. The 
chosen dose therefore allows for an increase in exposure due t o CYP3A4 inhibit ion without any  
potenti al safety  concerns. The PKof TAK -906 have al so been shown to be dose proportional 
across the dose range 5 to 300 mg and apparent clearance, vo lume of distribut ion and terminal 
eliminat ion half -life were all dose inde pendent .The effect of itraconazole on TAK -906 PK would 
therefore be expected to be consistent across this dose range.
6.2.2 Rationale for Endpoints
6.2.2.1 PK Endpoints
The primary  endpoint for thi s trial  consists of standard PK variables (C max, AUC last, and AUC ∞) 
thatare used to determine the effect of itraconazole on the PK of TAK- 906 in healt hy subjects.
6.2.2.2 Safety Endpoints
Key safet y endpo ints will be assessed through monitoring of AEs, vital signs, ECGs, clinical 
laboratory  resul ts,and physical examinat ions.
6.2.2.3 Exploratory Endpoints
6.2.3 Critical Procedures Based on Trial Objectives: Timing of Procedures 
For thi s trial, the collect ion ofthe blood sam ples for TAK -906 (PK) i s the cri tical procedure. 
At any postdose time point, the blood samples for TAK -906 (PK) need to be collected as close 
to the exact nominal t ime point as possible.
All other procedures should be co mpleted as close as p ossible, either before or after the 
prescribed/scheduled time.
ECG and vital signs measurements should be performed before the no minal t ime of the 
TAK -906 PK sampling, if scheduled together.
The order of priorit y can be changed during the trial with jo int agreem ent of  the invest igator 
and the sponsor.
Any nonscheduled procedures required for urgent evaluat ion of safet y concerns take 
precedence over all routine scheduled procedures.
CCI
TAK -906
Study No. TAK -906-1003 Page 19of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL6.3 Trial Beginning and End/Completion
6.3.1 Definition of Beginning of the Trial
The overall tri al begins when the first subject signs the trial informed consent form.
6.3.2 Definition of End of the Trial
The overall trial ends when the last subject completes the last planned or fo llow-up 
visit/interact ion associated with a planned visit (this c an be a phone contact), discont inues fro m the 
trial or is lost to f ollow-up (ie, the investi gator i s unable to contact the subject).
6.3.3 Definition of Trial Discontinuation
Trial discont inuat ion because of nonsafet y reasons, such as:
A finding (eg, PK, PD, eff icacy, bio logic targets) from another nonclinical or clinical trial 
using the trial treatment(s) results in the trial being stopped for a nonsafet y-related reason. 
Data from co mparator(s), drug(s) of the same class, or methodology(ies) used in this trial 
beco me available and results in the trial being stopped for a nonsafet y-related reason. 
The tri al is stopped because of nonscientific and nonsafet y reasons, such as slow enrollment.
Trial discont inuat ion because of safet yreasons: 
Early trial terminat ionbecause of unant icipated concerns o f safety  to the trial  subjects arising 
from clinical or preclinical trials wit h the trial treatment(s), comparator(s), drug(s) of the same 
class, or m ethodol ogy(ies) used in this trial.
6.3.4 Criteria for Premature Termination or Suspension of the Trial
6.3.4.1 Criteria for Premature Termination or Suspension of Trial Sites
A trial site may  be terminated prem aturely  or suspended if the site (including the invest igator) is 
found in significant vio lation of Good Clinical Practice ( GCP ), protocol, or contractual agreement, 
is unable to ensure adequate performance of the trial, or as otherwise permitted by the contractual 
agreem ent.
6.3.4.2 Procedures for Premature Termination or Suspension of the Trial or the Participation of 
Trial Site(s)
In the event that the sponsor, an institutional review board ( IRB) , or regulatory  authori ty elects to 
terminate or suspend the trial or the participat ion of an invest igational site, a trial -specific 
procedure for early terminat ion or suspensio n will be provided by the sponsor; the procedure will 
be fo llowed by applicable invest igational sites during the course of terminat ion or trial suspension.
TAK -906
Study No. TAK -906-1003 Page 20of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.1 Inclusion Criteria 
In order to be eligible for participat ion in this trial, the subject m ust:
1.Understand the trial procedures and agree to participate by  providing wri tten inform ed 
consent.
2.Be willing and able to comply with all trial procedures and restrict ions.
3.Be a man or wom an(with no child bearing potential) aged 18 to 55 years, inclusive, at the 
Screening Visit. 
4.Have a body mass index (BMI) ≥18 and ≤30 kg/m2and a body weight >50 kg at the Screening
Visit.
5.Be a nonsmoker who has not used tobacco -or nicotine -containing products (eg, nicotine 
patch) for at least 6 months before administration of the init ial dose of tri al drug/invasive 
procedure.
6.Be judged to be in good health by the invest igator, based on clinical evaluat ions including 
laboratory  safety tests, m edical his tory, physical  examinat ion, 12 -lead ECG, and vital sign 
measurements performed at the Screening Visit and before administration of the init ial dose of 
trial drug.
7.Meet the fo llowing bi rth control  requi rements:
–Is a m ale subject* who i s sterile or agrees to use an appropriate method of contraception, 
including a condom with spermicide, from trial drug administration on the first day  of the 
first dose until  5 half -lives pl us 90 days after administration of the last dose of trial drug. 
No restrict ions are requ ired for a vasectomized male subject provided the subject is at least  
1year post –bilateral vasectomy procedure before trial drug administration on the first day  
of the first dose. A male subject whose vasectomy  procedure was perform ed less than 
1year bef ore tri al drug administrati on on the first day  of the first dose must follow the 
same restrict ions as a nonvasectomized man. Appropri ate documentati on of  surgi cal 
procedure should be provided.
–Is a male subject who agrees to not donate sperm from trial dru g administration on the first  
day of the first dose until 5 half -lives plus 90 day s after administrati on of  the l ast dose of 
trial drug.
–Is a female subject *with no childbearing potential, defined by at least 1 of the fo llowing 
criteria:
a)Postmenopausal  (defined as 12 m onths of spontaneous amenorrhea in females aged 
>45 y ears, 6 months of spontaneous amenorrhea in females aged >45 years with seru m 
follicle stimulat ing horm one ( FSH)levels >40 m IU/m L). A high FSH level in the 
postm enopausal range (FSH >40 IU /L) may be used to confirm a post -menopausal 
state in younger women (eg, those <45 year old) or wom en who are not using hormona l 
TAK -906
Study No. TAK -906-1003 Page 21of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALcontraception or hormonal replacement therapy. However, in the absence of 12 mo nths 
of amenorrhea, a single FSH measurement is insufficient .Appropriate documentation 
of FSH l evels is requi red.
b)Surgically sterile by  hysterectomy  and/or bilateral  oophorectomy  with appropri ate 
docum entati on of  surgical  procedure.
c)Had a tubal ligat ion with appropri ate docum entati on of  surgical  proced ure.
d)Has a congenital condit ion result ing in no uterus.
*Details o f contraception and pregnancy  procedures are found in Appendix E.
7.2 Exclusion Criteria
The subject mus t be excluded fro m participat ing in the trial if the subject: 
1.Subjects who have a history  of clinically  significant endocrine, gastrointestinal (including 
motility disorder and intestinal obstruction), cardiovascular, hematological, hepat ic, 
immuno logical , renal , respi ratory , geni tourinary , or m ajor neurol ogical (including stroke and 
chronic seizures) abnormalit ies or diseases will be excluded fro m the trial.
2.Has parti cipated in another invest igational tri al within 4 weeks before the pretrial visit 
(Screen ing). The 4 -week window will be derived from the date of the last trial procedure 
and/or AE related to the trial procedure in the previous trial to the pretrial/Screening Visit of 
the current trial. 
3.Is an emplo yee or immediate family member (eg, spouse, p arent, child, sibling) of the sponsor.
4.Has a history  of cancer (malignancy).
5.Has a history  of significant m ultiple and/or severe allergies (eg, food, drug, latex allergy ) or 
has had an anaphylact ic reaction or significant intolerabilit y to prescript ion or nonprescript ion 
drugs or food.
6.Has a posit ive alcoho l or drug screen.
7.Is a l actati ng/nursing wo man.
8.Had major surgery , donated or l ost 1 unit of blood (approximately 500 mL) within 8weeks of
the first dose of study  drug . 
9.Has a known hypersensit ivity to any co mponent of the formulat ion of TAK -906 or related 
compounds, or to i traconazol e (see Product Insert).
10.Is unable to refrain fro m or anti cipates the use of any  medicat ion, including prescript ion and 
nonprescript ion drugs or herbal remedies, beginning app roximately 7 days before 
administration of the init ial dose of trial drug, throughout the trial (including washout intervals 
between tri al periods), until  the Foll ow-
up V isit. There may be certain medications that are 
permitted, see Section 7.3.
TAK -906
Study No. TAK -906-1003 Page 22of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL11.Has a history  of alcohol  consum ption exceeding 2 standard drinks per day on average (1 glass 
is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or dist illed 
spirits [29.5 mL/1 ounce] per day ).
12.Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately 
equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated 
bever ages per day .
13. Has a substance abuse disorder.
TAK -906
Study No. TAK -906-1003 Page 23of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL7.3 Excluded Medications ,Supplements, Dietary Products
Use of excluded agents (prescription or nonprescription) or dietary products is outline in Table 7.a.
Table 7.a Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and Enrollment 
(Days -28 to Predose [Day 1])Randomization Pos t-Enrollment 
(Day 1) to Follow -up
Tobacco -and 
nicotine -containing 
productsCompletely restricted Completely restricted
Cannabis products Completely restricted Completely restricted 
Alcohol Completely restricted 7 days before 
dosingCompletely restricted 7 days before 
dosing 
At all other times no more than 
3units/day
Xanthine and/or caffeine Completely restricted 48 hours before 
dosingCompletely restricted 48 hours before 
dosing 
At all other times no more than 
6units/day
Medications Completely restricted 7 days before 
dosingCompletely restricted (a)
Food substance
Grapefruit /grapefruit 
juiceCompletely restricted 7 days before 
dosingCompletely restricted
Fruit No restriction No restriction
Fruit juice No restrictio n Dosing will occur without consumption 
of fruit juice. Fruit juice is restricted 4 
hours after dosing.
Mustard green (b) Completely restricted 7 days before 
dosingCompletely restricted
Charbroiled meat Completely restricted 7 days before 
dosingCompletely restricted
(a) If medications are required to treat an AE, certain medications may be allowed after discussion and agreement 
between the sponsor and principal investigator.
(b) Mustard green family includes kale, broccoli, watercress, collar d greens, kohlrabi, Brussel sprouts, and mustard.
7.4 Diet, Fluid, Activity 
7.4.1 Diet and Fluid
Subjects m ust abstain fro m all food and drink (except water) at least 8 hours before any  clinical  
laboratory  evaluat ions. In addit ion, both doses of TAK -906 will be administered after an overnight 
fast of at least 8 hours as food reduces its bioavailabilit y by approximately 40%. 
The bioavailabilit y of itraconazol e when administered as a PO solut ion is increased under fasted 
compared wi th fed condi tions; t herefore, itraconazole will be administered as fasted on Day  4 of 
TAK -906
Study No. TAK -906-1003 Page 24of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALPeriod 2. A moderate -fat breakfast or snack may  be administered on i traconazol e-only days to 
alleviate gastrointestinal irritat ion. Itraconazole will be administered to subjects under clinic
supervisio n on an outpatient basis on the morning of Days 1 to 3 of Period 2.
During confinement (optional), l unch will be provided approximately 4 hours after TAK -906 
maleate dosing or 5 hours after itraconazole dosing, as applicable, on all days. Dinner will be 
provi ded approximately 9 or 10 hours after TAK -906 maleate or itraconazo le dosing, respectively, 
on all days. An evening snack will also be permitted. The caloric content and composit ion of meals 
will be the same in each trial period. Af ter the 24 -hour postdose (Day 2 of Trial Peri od1 and Day 
5 of Trial Period 2) procedures have been completed, subsequent meals and snacks will be 
unrestri cted in caloric content, composit ion, and timing.
7.4.2 Activity
Subjects will avo id unaccustomed strenuous physical activity (eg, wei ght lift ing, running, 
bicycling) from the Screening Visit until the Fo llow-up visit .
7.5 Criteria for Discontinuation or Withdrawal of a Subject
1.The subject experiences an AE that requires early terminat ion because cont inued participatio n 
impo ses an unacceptable risk to the subject’s healt h or the subject is unwilling to continue 
because of the AE.
2.Liver functi on test(LFT) abnormalit ies
In multidose studi es, tri al drug shoul d be discont inued immediately wit h appropriate clinical 
follow-up (inc luding repeat laboratory tests, until a subject’s laboratory profile has returned to 
norm al/baseline status, see Section 10.2.9.4 ), if the fo llowin g circumstances occur at any  time 
during tri al drug treatm ent:
–Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >8 times the 
upper limit of normal (ULN), or
–ALT or AST >5×ULN and persists for more than 2 weeks, or
– ALT or AST >3×ULN in con junct ion with elevated total bilirubin >2×ULN or 
internat ional norm alized rati o >1.5, or
–ALT or AST >3×ULN with appearance of fat igue, nausea, vomit ing, ri ght upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
3.Significant protocol  deviat ion. The discovery  that the subject failed to meet protocol entry  
criteria or di d not adhere to protocol requirements, and cont inued participat ion poses an 
unacceptable risk to the subject’s healt h.
4.Lost to follow -up. The subject did not return to the clinic, and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
docum entation.
TAK -906
Study No. TAK -906-1003 Page 25of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL5.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from the trial. The reason for withdrawal, if provided, should be recorded in the 
electroni c case report form (eCRF). 
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reaso n shoul d be recorded (i e, wi thdrawal because of 
an AE should not be recorded in the “vo luntary withdrawal” category ).
6.Trial terminat ion. The sponsor, IRB, or regulatory  agency  terminates the tri al.
7.6 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s trial participat ion at any  time during the trial when 
the subject m eets the tri al terminat ion criteria described in Sect ion 7.5. In addit ion, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the trial. Should a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the invest igator. In addit ion, efforts should be made to perform all procedures scheduled for the 
Early Terminat ion Visit. 
7.7 Subject Replacement
If a subject discont inues from the trial, a replacement subject may be enro lled, if deemed 
appropriate by  the invest igator and sponsor. The trial site should contact the sponsor for the 
replacement subject’s treatment assignment and allocation number. 
TAK -906
Study No. TAK -906-1003 Page 26of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL8.0 CLINICAL TRIAL MATER IAL MANAGEMENT
8.1 Clinical Trial Drug 
Details regarding the composit ion and extemporaneous preparatio n of the active ingredient are 
found in the Pharmacy  Manual, Com pounding Instructi ons, and/or similar documents. Clinical 
trial drug will  be packaged to support enrollment and replacement subjects as required. When a 
replacement subject i s requi red, the sp onsor needs to be contacted before dosing.
Itraconazole will be supplied by the trial site.
8.1.1 Clinical Trial Drug Labeling
Clinical trial drug packaging will be affixed wit h a clinical label in accordance with regulatory 
requi rements.
8.1.2 Clinical Trial Drug Inv entory and Storage
Clinical trial drug must be stored in a secure, limit ed-access locat ion under the storage condit ions 
specified on the label. Inventory  (recei pt and di spensing) of trial drug must be recorded by  an 
authori zed person at the trial site. 
8.1.3 Clinical Trial Drug Blinding
This is an open -label trial; therefore, the sponsor, investigator, and subject will know the treatment  
administered.
8.1.4 Accountability and Destruction of Sponsor- Supplied Drugs
The invest igator is responsible for keeping accurate re cords of the clinical trial drug received from 
the sponsor or designee, the amount dispensed to and returned by  the subjects, and the amount 
remaining at the conclusio n of the trial. For all trial sites, the local country  sponsor personnel or 
designee will provi de appropri ate docum entati on that m ust be com pleted for clinical trial drug 
accountabilit y, return, and destruction. 
8.1.5 Ancillary Supplies
All ancillary supplies will be provided by eit her the site or Takeda, based upon availabilit y. If 
provi ded by Tak eda, unused ancillary supplies will be accounted for and disposed of as directed by 
Takeda or a Takeda designee.
TAK -906
Study No. TAK -906-1003 Page 27of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL9.0 TRIAL PROCEDURES
The fo llowing sect ions describe the trial procedures and data to be collected as indicated in the 
Schedule of Trial Procedures (Section 3.0). For each procedure, subjects are to be assessed by the 
same investigator or site personnel whenever possible. Please note that it may beco me necessary to 
perform  the f ollowing procedures at unscheduled time periods, per the discret ion of the 
investigato r. For informat ion regarding procedures that are scheduled concurrent ly, see 
Secti on6.2.3 .
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
Inform ed consent m ust be obtained before the subject entering into the trial and before any  
protocol -directed procedures are performed. The requirements of informed consent are described 
in Section 13.2. 
9.1.2 Assignment of Screening Numbers
All consented subjects will be given a unique screening number that will be used to identify the 
subject for all procedures that occur before allocation. Each subject w ill be assigned only 
1screening number. Screening numbers must not be re -used for different subjects. Any  subject 
who is screened mult iple times will be assigned a new screening number for each screening event.
9.1.3 Inclusion and Exclusion Criteria 
Each subje ct is assessed according to the eligibilit y criteria provi ded in Sect ion 7.0.
9.1.4 Medical History/Demographics
Qualified site personnel are to collect su bject si gnificant m edical  history  (past and ongoing) per 
the site’s standard of care and appropriate clinical judgment as well as subject demographics. 
9.1.5 Prior and Concomitant Medication Review
Medicat ions are defined as prescription and over -the-counter dr ugs, vitamin supplements, 
nutraceuticals, and oral herbal preparat ions. Qualified site personnel are to review subject 
medicat ion use. 
9.1.6 Physical Examinations
Qualified site personnel will conduct physical examinat ions.
9.1.7 Vital Sign Measurements
Body  temperat ure will be measured with an oral (temperature taken at floor of the mouth) or 
tympanic thermo meter. The same method (eg, oral or tympanic) must be used for all subsequent 
measurements for each individual subject and should be the same for all subjects.
TAK -906
Study No. TAK -906-1003 Page 28of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALSubjects should rest in a semirecumbent position for at least 5 minutes before having vital sign 
measurements obtained. Vital signs will include heart rate ( HR), systolic bl ood pressure, and 
diastolic blood pressure. The same method (eg, same and appropriately sized cuff, manual or 
autom ated) m ust be used for all measurements for each individual subject and should be the same 
for all subjects. 
Subjects will cont inue to rest in a semirecumbent posit ion from the time of dosing unt il 4 hours 
postdose except to stand for the measurement of standing vital signs (if needed) or other 
trial-related procedure. 
9.1.8 Height and Weight
Body  weight and height will be obtained with the subject’s shoes off and jacket or coat removed.
9.1.9 BMI
BMI equals a person’s weight in kilograms divided by  height in meters squared (BMI=kg/m2). 
BMI will be rounded to the nearest whole number according to the standard convent ion of 
0.1to0.4 round down and 0.5 to 0.9 round up.
9.1.10 12-Lead ECG
Speci al care mu st be taken for proper lead placement by qualified personnel. Skin should be clean 
and dry  before lead placement. Subjects may need to be shaved to ensure proper lead placement. 
Female subjects may need to remove their bras. 
Subjects should be resting in a semirecumbent position for at least 5 minutes before each ECG 
measurement.
QT intervals wit h Fridericia correction method (QTcF) will be used to calculate QT intervals in 
this trial.
Before each trial period, a predose ECG will be obtained within approxi mately  30minutes before 
dosing. This m easurement will be used as the B aseline. The principal invest igator should arrange 
to have a trial cardio logist available as needed to review ECG tracings with abnormalit ies.
If a subject demonstrates an increase in QTcF interval ≥40 msec co mpared with a predose baseline 
measurement, the ECG will be repeated within 5 minutes. The average value o f the QTcF interval 
from the 2 ECGs will represent the value at that time point. If the average QTcF interval increase 
from Baseline for any  postdose time point is ≥40 msec, the subject will cont inue to be monitored 
by repeat 12 -lead ECGs every 60 minutes for at least 4 hours or until the QTcF is within 40 msec of 
the baseline value. If prolongation o f the QTcF interval ≥40 msec persists, a consultat ion with a 
trial cardi ologist may  be appropri ate and the sponsor should be notified.
If the QTcF interval is ≥500 msec, the sponsor should be notified and the ECGs should be 
reviewed by  a cardi ologist. The subject shoul d be tel emetry -monitored (until  the QTcF i s 
<500 msec) or should be considered for transfer to a location where clo ser monitoring is available.
TAK -906
Study No. TAK -906-1003 Page 29of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALIf the subject has unstable hemodynamics, or has any clinically significant dysrhyt hmias noted on 
telemetry , the subject should be immediately  transferred to an acute care setting for definit ive 
therapy . 
If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in place or 
mark the posit ion of the electrodes for subsequent ECGs. To mark the positi on of  the el ectrodes, 
12-lead electrode sites will be marked on the skin of each subject with an ECG skin marker pen to 
ensure reproducible electrode placement.
The fo llowing ECG param eters will be recorded: HR, PR -interval, QRS -durati on, QT -interval, 
QTcF -interval, and the interpretation of the ECG profile by the principal investigator. 
9.1.11 AE Monitoring
AE monitoring begins after signing of informed consent. A complete descript ion of AE collect ions 
and procedures is provided in Sect ion10.2.9 .
9.2 Laboratory Procedures and Assessments
Laboratory  samples will be collected in accordance with acceptable laboratory  procedures. 
Samples will be taken after a minimum 8 -hour overn ight fast on the days stipulated in the Schedule 
of Trial Procedures (Section 3.0).
9.2.1.1 Clinical Laboratory Tests
Chemistry 
Chemistry  evaluat ions will consist of the following standard chemistry  panel:
Albumin Alkaline phosphatase
ALT AST
Blood urea nitrogen Calcium
Carbon dioxide Chloride
Creatinine Glucose
Gamma -glutamyl transferase Sodium
Potassium Bilirubin (total), if above ULN, will be fractio nated
Protein (total)
TAK -906
Study No. TAK -906-1003 Page 30of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALHematology
Hem atology will consist of the following tests:
Erythrocy tes (red blood cells [RBCs]) Hemoglobin
Hematocrit Platelets
Leukocytes (white blood cells [WBCs]) with absolute 
differential
Urinalysis
Urinalysis will consist of the following tests:
Protein Glucose
Blood Nitrite
Urine microscopy  will be perform ed if urinalysis is abnormal. Microscopy  consists of 
RBC/high -power field, WBC/high -power field, and casts.
Urine Drug Screen
A urine drug screen will include the fo llowing tests: 
Amphetamines 3,4-methy lenedioxy -methamphetamine 
Barbiturates Methadone/metabolite
Benzodiazepines Opiates
Bupreno rphine/metabolite Oxycodone/oxy morphone
Cannabinoids Phency clidine
Cocaine/metabolites Cotinine
Alcohol Screen
Subjects will undergo a urine alcoho l test. An alcoho l breath test m ay be perform ed at the 
discreti on of  the invest igator.
9.2.1.2 Screening
Serum
Serum  evaluat ions will include the fo llowing tests:
β–human chorionic gonadotropin ( women only) FSH ( women only).
HIV test Hepatitis panel, including hepatitis B surface antigen and
anti-hepatitis C virus .
TAK -906
Study No. TAK -906-1003 Page 31of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL9.3 PK and PGx Samples
A porti on of  the DNA sample will be analyzed for the presence of allelic variants in drug 
metabo lizing enzymes, drug transporters, or putative drug targets that may contribute to the 
variabilit y in the PK of TAK -906 (Drug Metabolism Enzymes and Transporter s). 
As PGx is an evo lving science, many genes and their funct ions are not yet fully understood. Future 
data m ay suggest a rol e of these genes in drug response, which may lead to addit ional 
hypothesis -generating exploratory research and diagnostic developm ent on stored samples.
Samples for PK analysis will be collected as specified in the Schedule of Trial Procedures 
(Secti on3.0). Please refer to the Laboratory Manual for informat ion on the collect ion, processing, 
and shipment of samples to the central laboratory . 
It is ant icipated that the total blood volume drawn for the tri al will be approximately 180 mL. 
Primary specimen co llection parameters are provided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
DerivativeDescription of Intended 
UseSample 
Collection
Plasma sample for TAK -906 PK Plasma PK measurements Mandatory
Blood sample for DNA PGX Blood DNA PGx measurements Mandatory
Blood sample for RNA PGX Blood RNA PGx measurements Mandatory
9.3.1 PK Evaluations 
The PK parameters of TAK -906 will be derived using noncompartmental analysis methods and 
will be determined from the concentration -time data for all evaluable subjects. Actual sampling 
times, rather than scheduled sampling times, will be used in all PK computations invo lving 
sampling t imes. A more detailed descript ion will be given in the clinical pharmaco logy analysis 
plan.
The fo llowing pl asma PK parameters for TAK -906 will be calculated on Day  1 of Trial Period 1 
and Day 4 o f Trial Peri od 2: 
Cmax.
AUC ∞.
t1/2.
Other PK parameters may be calculated if deemed necessary for the interpretati on of  the data. All 
efforts will be made to obtain the PK samples at the exact no minal t ime relat ive to dosing. 
However, samples obtained wit hin 10% o f the no minal t ime fro m dosing will not be captured as a 
protocol  deviat ion, as l ong as the exact time of the sample collect ion is noted on eCRF.
CCI
TAK -906
Study No. TAK -906-1003 Page 32of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL9.3.2 PGx Measurements
9.3.2.1 Blood Sample for DNA and RNA PGx Measurements
When sampling of who le blood for PGx analysis occurs, every subject must sign an informed 
consent/be consented in order to participate in the trial. PGx is a co mponent of the trial; 
participat ion is mandatory .
PGx i s the study  of variations of DNA and RNA characterist ics as related to drug response. There 
is increasing evidence that an individual’s genet ic background may impact the PK ( absorpti on, 
distribut ion, metabo lism, and excretion ), pharmacodynamics (pharmacologic effects), and/or the 
clinical outcome (efficacy and/or safet y).
PGx research in this trial may  be conducted to understand how individual genet ic variat ion in 
subjects impacts their trial drug treatment response. This information may be also be used, for 
example, to develop a better understanding of the safet y and effic acy of TAK -906 and other tri al 
drugs, to increase understanding of the disease/condit ion being studied and other related 
condi tions, gain a better understanding of the drug pharmaco logy and f or generating information 
needed for research, development, and r egulatory  approval  of tests to predi ct response to 
TAK -906. 
Who le blo od samples for DNA and RNA iso lation will be collected fro m each consented subject in 
the trial. If necessary  and f easible, a second aliquot of blood may be taken at a later time point i f 
isolation of DNA fro m the first sam ple was not successful or possible.
Since PGx is an evo lving science, many genes and their funct ions are not y et fully understood. 
Future data may  suggest a rol e of these genes in drug response, which may lead to additi onal 
hypothesis -generating exploratory  research and diagnostic development on stored samples.
Detailed instructions for the handling and shipping of samples are provided in the Laboratory  
Manual.
9.3.2.2 Biological Sample Retention and Destruction
In thi s trial, specimens for genome/gene analysis will be co llected as described in the Laboratory 
Manual. The genet ic material will be init ially stored at thevendor, or a comparable laboratory , 
under contract to Takeda, with validated procedures in place, and then prese rved and retained at 
the vendor, or a comparable laboratory with validated procedures in place, for up to but not longer 
than 15 y ears f rom the end of the trial when the trial report is signed, or if less, the maximum 
period permitted under applicable law or until consent is withdrawn.
The sponsor and vendors working wit h the sponsor will have access to the samples collected and 
any test results. All samples collected during the trial will be stored securely wit h limited access 
CCI
TAK -906
Study No. TAK -906-1003 Page 33of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALand the sponsor will require anyone who works with the samples to agree to hold the research 
inform ation and any results in confidence.
The sample will be labeled wit h a u nique sample ident ifier as in the main trial but using a code that 
is different fro m the code attached to the heal th inform ation and other clinical test results collected 
in the trial. The sample and data are linked to personal healt h informat ion with code numbers; the 
samples are stripped of all personal ident ifying information but a key  linking the samples to 
clinic al analysis data exists. This link means that the subject may be identified but only indirect ly. 
The sample ident ifier will be kept secure by or on behalf o f the sponsor.
Subjects who consented and provided a pharmacogeno mic sample for DNA and RNA analysis can 
withdraw their consent at any time and request disposal of a stored sample. Any remaining sample 
that can be ident ified as coming fro m the subject will be destroy ed. The tri al doctor and sponsor 
may cont inue to use and distribute any information and t est results gathered before the request to 
withdraw.
9.4 Trial Drug Administration
Eligible subjects will be allocated to trial treatm ent by nonrando m assignment on Period 1 Day 1 to 
receive PO TAK -906 m aleate 25 m g capsule QD on Peri od 1 Day  1 and on Peri od 2 Day 4 at 
approximately  the same t ime ( between 0600 and 0900 ). 
In Peri od 2, subjects will receive PO itraconazole 200 mg so lution QD on Day s 1 to 5 at 
approximately  the same t ime ( between 0600 and 0900 ). Itraconazole will be administered to 
subjects under supervisio n on an outpatient basis on the morning o f Days 1 to 3 ofPeriod 2. On 
Day 4, TAK -906 m aleate will be administered 1 hour after itraconazole. 
9.5 Confinement
Period 1:
Subjects will report to the CRU the evening before the scheduled day o f administration (Day -1) of 
the trial drug at the discret ion of the invest igator. Subjects will remain in the unit unt il after the PK 
sample collect ion at 48 hours after TAK- 906 m aleate dosing (the morning of Day 3). At the 
discreti on of the invest igator, subjects may be requested to remain in the CRU longer.
Period 2:
Subjects will report to the CRU the evening of Day 3 before the scheduled day o f administration o f 
the trial drug on Day  4 and at the discretion of the investigator. Subj ects will remain in the unit 
until after the PK sample collection at 48 hours after TAK -906 m aleate dosing (the morning of 
Day 6).At the discret ion of the invest igator, subjects may be requested to remain in the CRU 
longer.
TAK -906
Study No. TAK -906-1003 Page 34of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a trial; it does not necessarily  have to have a causal 
relationship with the treatment.
An AE can ther efore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally ma y:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedur e.
Requi re discont inuat ion or a change in dose of trial medicat ion or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis . Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findi ngs:
Changes in laboratory  values or ECG param eters maybe considered to be AEs if they  are 
judged to be clinically  significant (i e, if som e act ion or intervent ion is required or if the 
investigator judges the change to be bey ond the range of normal physio logic fluctuati on). A 
laboratory  re-test and/or continued monitoring o f an abnorm alvalue are not considered an 
intervent ion. In addit ion, repeated or addit ional noninvasive testing for verificat ion, evaluatio n 
or monitoring of an abnormalit y is not conside red an intervent ion.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Pre-exist ing c onditions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as a n AE unless 
related to a trial procedure. However, if the subject experiences a worsening or complicat ion of 
TAK -906
Study No. TAK -906-1003 Page 35of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALsuch a concurrent medical history condit ion, the worsening or complicat ion should be recorded 
appropriately  as an AE (worsening or complicat ion occ urs after informed consent is signed). 
Invest igators should ensure that the event term recorded captures the change in the condit ion 
(eg, “worsening of…”).
If a subject has a pre -exist ing episodic condi tion(eg, asthma, epilepsy), any occurrence of an 
episode shoul d only  be captured as an AE if the episodes become more frequent, serious, or 
severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg “worsening of…”).
If a subject ha s a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which would be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
trial medicat ion or after any  change in trial medication, the worsening or com plicat ion shoul d 
be recorded as a new AE. Investigators should ensure that the AE term recorded captures the 
change in the condit ion (eg, “worsening of…”).
Changes in severit y of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in tri al medicat ion, the event should be captured once wit h the m aximum  severi ty recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of thepre-exist ing condit ion, the worsening o f 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting from any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs but shoul dbe documented in the subject’s source do cuments. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a trial subject, at a dose above that which is assign ed to that individual subject 
according to the trial protocol. It is up to the investigator or the reporting physician to decide 
whether a dose is to be considered an overdose, in consultation wit h the Sponsor.
All cases of overdose (with or without associ ated AEs) will be documented on an Overdose 
page of the eCRF, in order to capture this important safet y information consistent ly in the 
TAK -906
Study No. TAK -906-1003 Page 36of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALdatabase. AEs associated with an overdose will be documented on AE CRF(s) according to 
Secti on 8.1.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Sect ion 10.2.9 .
In the event of drug overdose, the subject shoul dbe treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.IsLIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPI TALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
TAK -906
Study No. TAK -906-1003 Page 37of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALTable 10.a Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respi ratory  
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal product Toxic epidermal necrolysis/
Stevens -Johnson syndromeNeuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner.
10.1.2 Special Interest AEs
An AEof special interest (serious or nonserious) is one of scient ific and medical concern specific 
to the compound or program for which ongo ing monitoring and rapid co mmunicat ion by the 
investigator to Takeda may be appropriate. Such events may require further invest igation in order 
to characterize and understand and would be described in protocols and instructions provided for 
investigators as to h ow and when they  should be reported to Takeda.
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different cat egories o f severit y/intensity are:
Mild: The event is transient and easily tolerated by the subject.
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
10.2.2 Assigning Causality of AEs
The relationship of each AE to trial medicat ion(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (includ ing the 
course after withdrawal of the drug), or for which possible involvement of the drug can be 
argued, although factors other than the drug, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments, may also be responsibl e.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments.
TAK -906
Study No. TAK -906-1003 Page 38of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL10.2.3 Assigning Relationship to Trial Procedures
Relationship (causalit y) to tri al procedures shoul d be determined for all AEs.
The rel ationship should be assessed as “Related” if the investigator considers that there is 
reasonable possibilit y that an event i s due to a tri al procedure. Otherwise, the relat ionship shoul d 
be assessed as “Not Related”.
10.2.4 Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by  the subject and/or 
investigator.
10.2.5 Stop Date 
The stop date of the AE is th e date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.2.6 Frequency 
Episodi c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous.
10.2.7 Action Concerning Trial Drug 
Drug withdrawn: a trial medicat ion is stopped because of the particular AE.
Dose not changed: the particular AE did not require stopping a trial medicat ion.
Unknown: only to be used if it has not been possible to determine what a ction has been taken.
Not applicable: a trial medicat ion was stopped for a reason other than the particular AE, for 
example, the trial  has been terminated, the subject died, dosing wit h trial medicati on was 
already stopped before the onset of the AE.
10.2.8 Outcome 
Recovered/reso lved: subject returned to first assessment status with respect to the AE.
Recovering/resolving: the intensit y is lowered by one or m ore stages; the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  valu e improved, but has 
not returned to the normal range or to the baseline value; the subject died fro m a cause other 
than the particular AE with the condit ion rem aining “recovering/resolving.”
Not recovered/not resolved : there i s no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, si gns/symptoms, or laboratory  value on the last day  of the observed 
trial period has becom e worse than when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the parti cular AE state remaining “Not recovered/not 
resolved.”
TAK -906
Study No. TAK -906-1003 Page 39of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALReso lved with sequelae: the subject recovered from an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal: an AE that i s considered as the cause of death.
Unknown: the course of the AE cannot be fo llowed up because o f hospital change or residence 
change at the end of the subject’s participation in the trial.
10.2.9 Collection and Reporting of AEs, SAEs, Special I nterest AEs, and Abnormal LFTs
10.2.9.1 Collection Period
Collect ion of AEs ( ie, AEs, SAEs, special interest AEs, and abnormal LFTs) will co mmence at the 
time the subject signs the informed consent. Routine co llection of AEs will cont inue unt il the 
Follow-up Vi sit 10 to 14 days after the last dose of TAK- 906. For subj ects who di scont inue prior 
to the administration of trial medicat ion, AEs will be fo llowed unt il the subject discont inues trial 
participat ion. 
10.2.9.2 Reporting AEs
At each trial visit, the invest igator will a ssess whether any subject ive AEs have occurred. A neutral 
question, such as “How have y ou been feeling since y our last visit ?” may be asked. Subjects may  
report AEs occurring at any  other time during the trial. Subjects experiencing an SAE prior to the 
first exposure to invest igational product must be monitored until the symptoms subside and any 
clinically relevant changes in laboratory values have returned to Baseline or there is a satisfactory 
explanat ion for the change. Nonserious AEs that begin prior to the first exposure to invest igational 
product, related or unrelated to the trial procedure, need not be followed -up for the purposes of the 
protocol .
All subjects experiencing AEs, whether considered associated with the use of the trial medication 
or not, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All AEs will be documented in the AE page of the eCRF, w hether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and stop date and time.
Severit y.
Invest igator’s opinio n of the causal relationship bet ween the event and administration of trial 
medicat ion(s) (rel ated or not rel ated).
Invest igator’s opinio n of the causal relationship to trial procedure(s), including the details of 
the suspected procedure.
TAK -906
Study No. TAK -906-1003 Page 40of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALAction concerning trial medicat ion.
Outcom e of event.
Seriousness.
10.2.9.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A Takeda SAE form must be co mpleted, in English and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the tri al medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 14.1.1 .
Any SAE spontaneously  reported to the investigator after the AE collect ion peri od shoul d be 
reported to the sponsor if considered related to trial participat ion.
Reporting of SAEs that begin before the first administrati on of investigational product will fo llow 
the sam e procedure for SAEs occurring on treatment.
SAE Follow -Up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if reque sted.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.9.4 Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST ele vated >3×ULN on 2 consecutive occasions, the 
abnorm ality shoul d be recorded as an AE. In addition, an LFT Increases eCRF must be co mpleted 
provi ding addit ional information on relevant recent history , risk factors, clinical signs and 
symptoms, and results o f any addi tional diagnosti c tests perform ed.
TAK -906
Study No. TAK -906-1003 Page 41of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALIf a subject is noted to have ALT or AST >3×ULN and total bilirubin >2×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on 10.2.9.3 . The i nvest igator must contact the Medical Monitor for discussio n of the 
relevant subject details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease. Follow -up laboratory  tests as described in Section
 9.2must also be 
perform ed. In addi tion, an LFT Increases eCRF must be completed and transmitted with the 
Takeda SAE form (as per Section 10.2.10 )
. 
10.2.10 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators and IRBs or 
independent ethics committees (I ECs), as applicable, in accordance wit h nat ional regulations in 
the countries where the trial is conducted. Relat ive to the first awareness of the event by/or further 
provi sion to the sponsor or sponsor’s designee, SUSARs will be submitted within 7 days fo r fatal 
and life -threatening events and 15 days for other seri ous events, unless otherwise required by  
national regulat ions. The sponsor will also prepare an expedited report for other safet y issues 
where these might materially  alter the current benefit -risk assessment of an investigational 
medicinal product or that would be sufficient to consider changes in the invest igational medicinal 
products administration or in the overall conduct of the trial. The invest igational site also will  
forward a copy  of all expedi ted reports to his or her IRB or IEC in accordance wit h nat ional 
regul ations.
TAK -906
Study No. TAK -906-1003 Page 42of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized before database lock. This 
docum ent will provi de further details regarding the definit ion of analysis variables and analysis 
methodol ogy to address all trial object ives.
A targeted data review will be conducted before database lock. This review will assess the 
accuracy  and com pleteness of the trial datab ase, subject evaluabilit y, or appropri ateness of the 
planned statistical methods.
11.1.1 Analysis Sets
11.1.1.1 Safety Set
The safet y set will consist of all subjects who are enro lled and receive at least 1 dose of trial drug. 
Subjects in this analysis set will be used fo r dem ographic, baseline characteristics, and safet y 
summaries.
11.1.1.2 PK Set
The PK set will consist of all subjects who are enrolled and receive at least 1 dose of trial drug and 
have at least 1 measurable plasma TAK- 906 concentrati on. All subjects with valid PK parameter 
estimates will be included in the summaries and analyses for that parameter.
If any subject is found to be nonco mpliant with the dosing schedule or has inco mplete data, a 
decisio n will be made on a case -by-case basis as to whether that subject s hould be included in the 
PK analyses; however, data for all subjects will be presented in the data list ings.
11.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographic and baseline characterist ics will be summarized for all subjects. Summary s tatistics 
(number of subjects, mean, SD, median, minimum, and maximum) will be presented for 
continuous variables (eg, age, weight, and BMI), and the number and percentage of subjects within 
each category  will be presented for categorical variables (eg, se x, ethnicit y, and race). Individual 
subject demographic and baseline characterist ic data will be provided in the data list ings.
11.1.3 PK Analysis
Concentrations of TAK- 906 and any measured metabolites will be summarized by  regimen over 
each scheduled sampling ti me using descript ive statist ics.
The am ount of  TAK -906 and any  measured m etaboli tes excreted in urine will be summarized by  
regimen using descript ive statistics. 
Individual plasma and urine concentration versus time data will be presented in a data list ing. 
TAK -906
Study No. TAK -906-1003 Page 43of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALPlasma and urine PK parameters of TAK -906 and any measured metabo lites will be summarized 
by regimen using descript ive statist ics. 
For evaluat ion of potenti al effect of i traconazol e on TAK -906 PK, pai red t-tests and associated 
90% confidence intervals (CIs) will be determined on the natural logarithms of C maxand AUCs to 
assess the exposure between regimens (TAK -906 maleate al one and TAK -906 m aleate wi th 
itraconazo le). The geometric mean of the relat ive bioavailabilit y of the TAK -906 m aleate wi th 
itraconazo le regimen relat ive to the TAK -906 m aleate al one regim en and the associated 90% CIs 
will be determined by exponent iating the appropriate estimates for the difference between 
regimens in the log -transform ed param eters.
A more detailed analysis will be presented in the SAP. Addit ional analyses will be included, if 
appropriate.
11.1.4 Safety Analysis
The safet y set will be used for all summaries of safety  parameters. These summaries will be 
presented by regimen (TAK -906 maleate alone, itraconazol e alone, and TAK -906 maleate with 
itraconazo le).
11.1.4.1 AEs
All AEs will be coded by system  organ cl ass (SOC) and preferred term (PT) using the Medical 
Dictionary for Regulatory  Activities (MedDRA). Treatment -emergent adverse events (TEAEs) 
with onset occurring within 30 days after the last dose of trial drug (onset date minus last date of 
dose +1 ≤30) will be included in the summary tables. All AEs will be in the list ings. TEAEs will be 
summarized by  SOC and PT. The following summary  tables will be included in the report: 
summary of TEAEs and drug -related AEs, relat ionship o f AEs t o trial drug (related vs not related), 
severit y of AEs, and SAEs. Data listings will be provided for all AEs including TEAEs, AEs 
leading to trial drug discontinuation, and SAEs.
11.1.4.2 Clinical Laboratory Evaluation
Baseline, postdose, and change fro m Baseline to pos tdose laboratory  data will be summarized by  
regimen. All clinical laboratory  data will be provi ded in the data list ings.
11.1.4.3 Vital Signs
Baseline, postdose, and changes from Baseline in vital sign measurements will be summarized. All 
vital sign data will  be provi ded in the data list ings.
11.1.4.4 ECGs
Baseline, postdose, and changes from Baseline in quant itative ECG parameters will be 
summarized by regimen. Shift tables for each will be generated to show the invest igator’s ECG 
interpretati ons at each postdose collecti on by  the interpretati on at Baseline.
All ECG data will be provided in the data list ings.
TAK -906
Study No. TAK -906-1003 Page 44of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL11.2 Interim Analysis and Criteria for Early Termination
No formal interim analyses will be conducted. 
11.3 Determination of Sample Size
Approximately  12 subjects will be enro lled in this trial. The sample size just ificat ion is based on an 
acceptance range of 50% to 200% and assumes that the intrasubject %CV for AUC lastand C maxof 
TAK -906 will not exceed 25%. This sample size will provide 80% power to conclude plasma 
concentra tion of  TAK -906 will not increase more than 2 -fold in presence of itraconazole.
Subjects who drop out for nonsafet y reasons may be replaced at the discretion of the invest igator in 
consultation wit h the sponsor. Subjects who drop out for safet y reasons wil l not be replaced.
TAK -906
Study No. TAK -906-1003 Page 45of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Trial -Site Monitoring Visits
Moni toring visits to the trial site will be made periodically during the trial to ensure that all aspects 
of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data recorded 
on the eCRFs. Source documents are defined as original documents, data, and records. The 
investigator and trial site guarantee access to source documents by the sponsor or its designee and 
by the IRB or IEC.
All aspects of the trial  and i ts documentati on will be subject to review by  the sponsor or the 
sponsor’s designee, including but not limited to the Invest igator’s Binder, trial drug, subject 
medical records, informed consent documentation, and review of eCRFs and associ ated source 
docum ents. It i s important that the invest igator and other trial personnel are available during the 
monitoring visits and that sufficient time is devoted to the process.
12.2 Protocol Deviations
The invest igator should not deviate fro m the protocol ,except where necessary to eliminate an 
immediate hazard to trial subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary trial assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The tri al site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and a ny other facilit y used during the trial. In 
addition, there is the possibilit y that thi s trial may  be inspected by  regulatory  agencies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Age ncy, the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
trial site is contacted for an inspect ion by a regulatory  body , the sponsor should be notified 
immediately . The investi gator guarantees access for qualit y assurance auditors to all trial
docum ents as described in Sect ion 12.1.
TAK -906
Study No. TAK -906-1003 Page 46of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL13.0 ETHICAL ASPECTS OF T HE TRIAL
This tri al will be conducted wi th the highest respect for the individual part icipants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the International Conference on Harmo nisat ion (ICH) Harmonised Tripartite 
Guideline for GCP. Each investigator will conduct the trial according to applicable local or 
regional regulatory  requi rements and align his or her conduct in accordance wit h the 
“Responsibilit ies of the Invest igator” that are listed in Appendix B.  The principles of Helsinki are 
addressed through the protocol and through appendices containing requirements for informed 
consent and invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has direct participation in this trial, written notificatio n regarding his or her abst inence fro m vo ting 
must also be obtained. Those Americas sites unwilling to provide names and tit les of all members 
because of privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for th e protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the trial (ie, before shipmen t of the sponsor -supplied drug or trial -specific 
screening activit y). The IRB or IEC approval must refer to the trial by exact protocol t itle, number, 
and versio n date; ident ify versio ns of other documents (eg, informed consent form) reviewed; and 
state the approval  date. The sponsor will ship drug/notify site once the sponsor has confirmed the 
adequacy  of site regul atory  docum entati on and, when applicable, the sponsor has received 
permission fro m competent authori ty to begin the trial. Unt il the site recei ves drug/notificat ion no 
protocol  activit ies, including screening, may  occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the inf ormed consent 
form, recrui tment m aterials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the trial at intervals specified by the 
respective IRB or IEC, and submissio n of the invest igator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects mu st 
be approved by the IRB or IEC and sponsor.
TAK -906
Study No. TAK -906-1003 Page 47of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL13.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the trial. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the trial, its object ives, and potential risks and benef its, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and, if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and su bject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor before use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language f ully comprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the trial, and (2) decide whether or not to participate in the trial. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the trial, then the informed consent form and subject authorization form (if applicable ) must be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
consent and before the subject entering into the trial. The subject or the subject’s legally acceptable 
representative should be instructed to sig n using their legal names, not nicknames, using blue or 
black ballpo int ink. The investigator must also sign and date the informed consent form and 
subject authorizat ion (if applicable) at the time of consent and before subject entering into the trial; 
however, the sponsor may  allow a designee of the investi gator to si gn to the extent permitted by  
applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
TAK -906
Study No. TAK -906-1003 Page 48of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALAll revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original info rmed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA and RNA analysi s can wi thdraw 
their consent and request disposal o f a stored sample at any  time before analysis. Notify  the 
sponsor of consent withdrawal.
13.3 Subject Confidentiality
The sponsor and designees affirm and uphol d the principle of the subject’s right to protecti on 
against invasio n of privacy. Throughout this trial, a subject’s source data will only be linked to the 
sponsor’s clinical trial database or documentation via a unique ident ificat ion number. As permitted 
by all applicable laws and regulat ions, limited su bject attributes, such as sex, age, or date of birth, 
and subject init ials may be used to verify the subject and accuracy  of the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designate d auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio nsoccurring during a subject’s trial part icipation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 13.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other iden tifier fields 
not collected on the subject’s eCRF).
13.4 Publication, Disclosure, and Clinical Trial Registration Policy
13.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from  the tri al. During and after the tri al, only  the sponsor m ay make tri al 
inform ation available to other trial investigators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical trial sit e agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or trial result s, other 
than tri al recrui tment materi als and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any  data and informat ion fro m the trial (including data and informat ion 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
TAK -906
Study No. TAK -906-1003 Page 49of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALthis secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Trial Registration 
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
interventional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along with invest igator’s cit y, state (forAmer ican investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating trial sites closest to their ho mes by 
provi ding the invest igator name, address, and p hone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor.
Any invest igator who objects to the sponsor providing this informat ion to callers must provid e the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site.
13.4.3 Clinical Trial Results Disclosure 
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as requi red by Takeda Policy/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Each subject in the trial must be insured in accordance wit h the regulat ions applicable to the site 
where the subject is participat ing. If a local underwri ter is requi red, then the sponsor or sponsor’s 
designee will obtain clinical trial insurance against the risk of injury to trial subjects. Refer to the 
trial site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.
TAK -906
Study No. TAK -906-1003 Page 50of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Trial Contact Information 
Contact Type/Role Contact
SAE and pr egnancy reporting Pharmacovigilance
Takeda Development Center Americas, Inc.
Fax: 224-554 -1052
TAK -906
Study No. TAK -906-1003 Page 51of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL15.0 INVESTIGATOR AGREEME NT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert and any  other product information provided by the sponsor. I agree to conduct this trial in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f trial subjects in accordance with the following:
The ethical principl es that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 10.2.10 of this protocol .
Terms outlined in the trial site agreement.
Responsibilit ies of the Invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in
 Appendix Dof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
TAK -906
Study No. TAK -906-1003 Page 52of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL15.1 Trial -Related Responsibilities 
The sponsor will perform all trial -related activit ies wi th the excepti on of  those i dentified in the 
Study -Related Responsibilit ies template. The vendors ident ified for specific trial -related activit ies 
will perform these act ivities in full or in partnership wi th the sponsor.
TAK -906
Study No. TAK -906-1003 Page 53of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL15.2 List of Abbreviations
%CV percent coefficient of variation
hCG human chorionic gonadotropin
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC last area under the concentration -time curve from time 0 to time of the last quantifiable 
concentration
AUC ∞ area under the concentration -time curve from time 0 to infinity, calculated using the 
observed value of the last quantifiable concentration
BMI body mass index
CFR Code of Federal Regulations
CI confidence interval
CL R renal clearance
Cmax maximum observed concentration
CNS central nervous system
CRU clinical research unit
CYP cytochrome P -450
DA dopamine
DNA deoxyribonucleic acid
DDI drug-drug interaction
ECG electrocardiogram
eCRF electronic case report form
EMA European Medicines Agency
EPS extrapy ramidal sy mptoms
fe fraction of administered dose of drug excreted in urine
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
HR heart rate
ICH International Conference on Harmonisation
IEC independent ethics committee
IRB institutional review board
LFT liver function test
MedDRA Medical Dictionary for Regulatory Activities
PD pharmacodynamics
PGx pharmacogenomics
PK pharmacokinetic(s)
PO oral(ly)
PT preferred term
TAK -906
Study No. TAK -906-1003 Page 54of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALQD once daily
QTcF QT interval with Fridericia correction method
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SOC system organ class
SUSAR suspected unexpected serious adverse reactions
t1/2 half-life
tmax time of first occurrence of C max
TEAE treatment -emergent adverse event
ULN upper limit of normal
WBC white blood cell
TAK -906
Study No. TAK -906-1003 Page 55of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL16.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, m edical history , and concurrent conditions will be coded using the MedD RA. Drugs will be 
coded using the World Healt h Organizat ion Drug Di ctionary.
16.1 eCRFs
Com pleted eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this trial to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data a re transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for s ignificant corrections should addit ionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit yfor the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of  the clinical trialdatabase, any  change of, m odificat ion of, or addit ion to the data 
on the eCRFs should be made by the investigator using change and modificat ion record s of the 
eCRFs. The principal invest igator must review the data change for completeness and accuracy, 
and must sign and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the trial site during periodic visits by 
trial monitors. The sponsor or its desi gnee will be permitted to review the subject’s medical and 
hospi tal records pertinent to the trial to ensure accuracy  of the eCRFs. The com pleted eCRFs are 
the sole property  of the sponsor and should not be made available in any form to third p arties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
16.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 16.1 and those documents that 
include (but are not limited to) the trial- specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, tempora ry media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, including the audit trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
TAK -906
Study No. TAK -906-1003 Page 56of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALdocum entati on printed on degradable thermal sensitive paper should be photoco pied by the site 
and filed wit h the original in the subject’s chart to ensure long -term legibilit y. Furthermore, ICH 
E6 Secti on 4.9.5 requi res the investigator to retain essent ial docum ents specified in ICH E6 
(Secti on 8) until at least 2 y ears after the l ast approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is not approved, until at least 2 years after 
the invest igation is discontinued and regulatory authorities are notified. In addit ion, ICH E6 
Section 4.9.5 states that the trial records should be retained unt il an amount of time specified by 
applicable regulatory  requi rements or for a time specified in the Clinical Study  Site Agreement 
between the invest igator and sponsor.
Refer to the Clinical St udy Site Agreement for the sponsor’s requirements on record retention. The 
investigator and the head of the institution should contact and receive written approval fro m the 
sponsor before disposing of any  such documents.
TAK -906
Study No. TAK -906-1003 Page 57of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL17.0 REFERENCES 
1.Parkm an HP, Hasl er WL, Fisher RS, American Gastroenterological A. American 
Gastroenterological Associat ion technical review on the diagnosis and treatment of 
gastroparesi s. Gastroenterology  2004;127(5):1592-622.
2.Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American Co llege o f G. Clinical 
guideline: m anagement of gastroparesis. Am J Gastroenterol 2013;108(1):18- 37; quiz 8.
3.Hyett B, Martinez FJ, Gill BM, Mehra S, Lembo A, Kelly CP, et al. Delayed radionucleotide 
gastri c empt ying studies predi ct morbidity in diabeti cs wi th symptom s of gastroparesis. 
Gastroenterology  2009;137(2):445-52.
4.Meltzer HY. Update on ty pical  and at ypical antipsychoti c drugs. Annu Rev Med 
2013;64:393 -406.
5.Michaud V, Turgeon J. Domperidone and sudden cardiac dea th: How m uch l onger shoul d we 
wait? J Cardi ovasc Pharmaco l 2013;61(3):215 -7.
6.Darm ani NA, Zhao W, Ahmad B. The ro le of D2 and D3 dopamine receptors in the mediat ion 
of emesis in Cryptoti s parva (the least shrew). J Neural Transm (Vienna) 
1999;106(11 -12):1045-61.
7.Kashyap P, Micci MA, Pasricha S, Pasricha PJ. The D2/D3 agonist PD128907 
(R-(+)-trans -3,4a,10b -tetrahy dro-4-propyl -2H,5H -[1]benzopy rano[4,3 -b]-1,4-oxazin - 9-ol) 
inhibits st imulated pyloric relaxat ion and spontaneous gastric empt ying. Dig Dis Sc i 
2009;54(1):57 -62.
8.Lee A, Kuo B. Metoclopramide in the treatment of diabet ic gastroparesis. Expert Rev 
Endocrino l Metab 2010;5(5):653 -62.
9.Yoshikawa T, Yoshida N, Hosoki K. Invo lvement of dopamine D3 receptors in the area 
postrem a in R(+) -7-OH-DPAT -induced em esis in the ferret. Eur J Pharmaco l 
1996;301(1 -3):143 -9.
10.Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The abdo minal 
visceral innervat ion and the emetic reflex: pathways, pharmacology, and plasticit y. Can J 
Physio l Pharm acol 1990;68(2):325 -45.
TAK -906
Study No. TAK -906-1003 Page 58of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL18.0 APPENDICES
TAK -906
Study No. TAK -906-1003 Page 59of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALAppendix ADetailed Description of Amendments to Text 
Change 1:Added addi tional serum  β-human chorioni c gonadotropin (hCG) tests.
The primary  change occurs in Secti on3.0Schedule of Trial Procedures :
Descript ion 
of change:Added h CG to tabl e at the following visits: Screening, Day  -1, End of 
Treatment/Early Terminat ionVisit
Rationale for Change :
Addit ion of serum hCG for all female subjects.
Change 2:Clarified use of follicle stimulat ing hormo ne (FSH) test.
The primary  change occurs in Section 7.1Inclusio n Cri teria:
Initial 
wording:a)Postmenopausal  (defined as 12 m onths of spontaneous amenorrhea in females 
aged >45 y ears, 6 m onths of spontaneous amenorrhea in females aged >45 y ears 
with serum  FSH levels >40 m IU/mL). Appropri ate docum entati on of  FSH levels 
is required.
Amended 
or new 
wording:a)Postmenopausal  (defined as 12 m onths of spontaneous amenorrhea in females 
aged >45 y ears, 6 m onths of spontaneous amenorrhea in females aged >45 y ears 
with serum  FSH levels >40 m IU/mL). A high FSH level in the postmenopausal 
range (FSH >40 IU/L) may be use d to confirm a post -menopausal state in 
younger women (eg, those <45 year old) or women who are not using 
hormonal contraception or hormonal replacement therapy. However, in the 
absence of 12 months of amenorrhea, a single FSH measurement is 
insufficient. Appropriate documentation of FSH levels is required.
Rationale for Change :
Provi de addi tional guidance for performing FSH to confirm postmenopausal status of female 
subjects <45 y ears of age.
TAK -906
Study No. TAK -906-1003 Page 60of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALChange 3: Extended the morning dosing time range for the TAK -906.
The primary  change occurs in Secti on 9.4Trial Drug Administrati on
Initial 
wording:Eligible subjects will be allocated to trial treatment by nonrando m assignment on 
Period 1 Day 1 to receive PO TAK -906 m aleate 25 mg capsule QD on Period 1 Day 1 
and on Peri od 2 Day  4 at approximately the same time (between 0600 and 0800). 
In Period 2, subjects will receive PO itraconazole 200 mg so lution QD on Days 1 to 5 
at approximately the same time (between 0600 and 0800). Itraconazole will be 
administered to subjects under supervisio n on an outpatient basis on the morning o f 
Days 1 to 3 of Period 2. On Day 4, TAK -906 maleate will be administe red 1 hour after 
itraconazo le.
Amended 
or new 
wording:Eligible subjects will be allocated to trial treatment by nonrando m assignment on 
Period 1 Day 1 to receive PO TAK -906 m aleate 25 mg capsule QD on Period 1 Day 1 
and on Period 2 Day 4 at approximately the same t ime (between 0600 and 0800 0900 ). 
In Period 2, subjects will receive PO itraconazole 200 mg so lution QD on Days 1 to 5 
at approximately the same time (between 0600 and 0800 0900 ). Itraconazole will be 
administered to subjects under supervisio n on an outpatient basis on the morning o f 
Days 1 to 3 of Period 2. On Day 4, TAK -906 maleate will be administered 1 hour after 
itraconazo le. 
Rationale for Change :
Acco mmo date subject procedures performed before dosing.
Change 4:Aligned timing and procedures for collection of AE throughout document.
The primary  change occurs in Section 9.1.11 AE Monitoring
Initial 
wording:AE m onitoring begins after si gning of informed consent. Changes in s ubject healt h 
status fro m baseline assessment to trial drug administration should be captured in the 
subject’s medical history .A complete description of AE co llections and procedures is 
provi ded in Sect ion10.2.9 .
Amended 
or new 
wording:AE m onitoring begins after si gning of informed consent. Changes in subject healt h 
status fro m baseline assessment to trial drug administration should be captured in the 
subject’s medical history .A complete description of AE co llections and procedures is 
provi ded in Sect ion10.2.9 .
Rationale for Change :
Removed sentence to align collect ion of AE data with Section 10.0 Adverse Events
TAK -906
Study No. TAK -906-1003 Page 61of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALChange 5:Removed data collect ion using digital wearable devices.
The primary  change occurs i n Section 10.2.9.3 Reporting SAEs :
Deleted 
text:
Rationale for Change :
Digital wearable devices will not be used in this study .
Change 6:Clarified birth control requirements for female partners of male subjects.
The primary  change occurs in Appendix EPregnancy and Contraception .
Initial 
wording:Male Subjects and Their Female Partners
From  signing o f informed consent, throughout the duration of the trial, and for 5 
half-lives PLUS 90 days after the last dose of trial drug, nonsterilized** male subjects 
who are sexually  active wi th a female partner of childbearing potential must use 
barrier contracept ion (eg, condom wit h or without spermicidal cream or jelly). In 
addition, they  must be advised not to donate sperm during this period. Women of 
childbearing potential who are partners of male subjects are also advised to use 
additional contracepti on as sho wn in the list containing highly effect ive/effect ive 
contraception below.
Amended 
or new 
wording:Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the trial, and for 5 
half-lives PLUS 90 days after the last dose of trial drug, nonsterilized** male subjects 
who are sexually  active wi th a female partner of childbearing potential must use 
barrier contraception (eg, condom wit h or without spermicidal cream or jelly). In 
addition, they  must be advised not to donate sperm during this period. Women of 
childbearing potential who are partners of male subjects are also advised to use 
additional contra cepti on as shown in the list containing highly effect ive/effect ive 
contraception below.
Rationale for Change :
Male birth control requirements will apply to all female partners of male subjects, regardless of the 
female partner’s child -bearing potenti al.
CCI
TAK -906
Study No. TAK -906-1003 Page 62of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALChange 7:Updated predose restrict ion for xanthine and/or caffeine use.
The primary  change occurs in Section 7.3Excluded Medicat ions,Supplements, Dietary Products ; 
Table 7.aExcluded Medications, Supplements, and Dietary Products
Descript ion 
of change:Changed length of xanthine and/or caffeine use predose from 24 to 48 hours.
Xanthine and/or caffeine Completely restricted 2448hours before 
dosingCompletely restricted 2448 hours before 
dosing 
At all other times no more than 
6units/day
Rationale for Change :Lengthened restri ction time for xanthine and/or caffeine use to ensure 
adequate washout before dose.
Change 8:Added urine cotinine as part of drug screen.
The primary  change occurs in Section 9.2.1.1 Clinical Laboratory  Tests :
Descript ion 
of change:Table: Urine Drug Screen
cotinine
Rationale for Change:
Added to urine drug screening because of involvement of CYP 1A2 with TAK -906’s mechanism 
of action.
TAK -906
Study No. TAK -906-1003 Page 63of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALAppendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summar ized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this trial.
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1. Conduct the trial in accordance wi th the protocol .
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
4.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all colleagues and emplo yees assist ing in the conduct of the trial are informed of 
these obligat ions.
6. Secure prior approval of the trial and any changes by an appropriate IRB/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and local regu latory requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the trial to the 
IRB/IEC, and issue a final report within 3 months of trial co mpletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9. Obtain valid informed con sent f rom each subject who participates in the trial, and document 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
trial. If an inform ed consent form  does not include such a subject authorizat ion, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the trial, including 
eCRFs, hospital recor ds, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years after notificat ion by the sponsor that all investigations have been discontinued or that 
the regulatory  authori ty has approved the m arketing applicat ion. The invest igator should 
TAK -906
Study No. TAK -906-1003 Page 64of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALcontact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
TAK -906
Study No. TAK -906-1003 Page 65of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALAppendix CElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the trial invo lves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the su bject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the trial.
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the trial.
9.A descript ion of the possible side effects of the treatment that the subject may receive.
10.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
11.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
12.Disclosures of appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
13.A statement describing the extent to which confident iality of records i dentifying the subj ect 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is auth orizing such access.
14.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further infor mation may be obtained.
15.The ant icipated prorated payment(s), if any, to the subject for participat ing in the trial.
16.The ant icipated expenses, if any , to the subject for parti cipat ing in the trial.
17.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
18.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefits to which the subject otherwise is entit led, and that the subject may discont inue 
participat ion at any  time wi thout penal ty or loss of benefits to which the subject is otherwise 
entitled.
TAK -906
Study No. TAK -906-1003 Page 66of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL19.The consequences of a subject’s decisio n to wi thdraw fr om the research and procedures for 
orderly terminat ion of part icipation by the subject.
20.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevan t to the subject’s 
willingness to continue participat ion in the trial.
21.A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the sponsor to do so.
22.The foreseeable circumstances or reasons under whic h the subject’s participat ion in the trial 
may be terminated.
23.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the trial. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, it s affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal heal th informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our person al information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better un derstanding of the 
safet y and effect iveness o f the trial medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the us e and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the trial to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that trial results are 
published.
24.Male subjects must use adequate contraception (as defined in the informed consent) from 
Screening, throughout the duration of the trial, and for 5 half -lives plus 90 days after last dose 
of trial medicat ion. If the partner or wife o f the subject is found to be pregnant during the trial, 
the invest igator will o ffer the subject the choice to receive treatment informat ion. 
TAK -906
Study No. TAK -906-1003 Page 67of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL25.A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
TAK -906
Study No. TAK -906-1003 Page 68of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALAppendix DInvestigator Consent to Use of Personal Information 
Takeda will co llect and retain personal information of inve stigator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United Stat es, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the trial and/or other clinical studies.
Management, monitoring, insp ection, and audit of the trial.
Analysis, review, and verificat ion of the trial results.
Safety reporti ng and pharmacovigilance relat ing to the trial.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agenci es rel ating to the trial.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the tr ial medi cation.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the trial.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of trial records.
Posting invest igator site contac t inform ation, trial details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
TAK -906
Study No. TAK -906-1003 Page 69of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIALAppendix EPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Female Subjects and Their Male Partners
Female subjects of childbearing potential are excluded fro m this tri al; there are no requirements 
for contracepti on or pregnancy  avoi dance.
Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the trial, and for 5 half -lives PLUS 
90 days after the last dose of trial drug, nonsterilized** male subjects who are sexually active with 
a female partner must use barrier contraception (eg, condom wit h or without spermicidal cream or 
jelly). In addition, they  must be advised not to donate sperm during this period. Women who are 
partners of male subjects are also advised to use addit ional contraception as s hown in the list 
containing highly effective/effect ive contraception below.
** Sterilized males should be at least 1 year post –bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral  
orchi dectomy .
1.Highly effect ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correctly ). In this tri al, where medications and devices containing hormones are included, 
females o f childbearing potential who are partners of male subjects are advised to use 
additional contracepti on chosen from the list belo w: 
Nonhorm onal methods: 
–Intrauterine device.
–Bilateral tuba l occlusion. 
Horm onal methods: 
–Combined (estrogen and progestogen) hormonal contraception associated with 
inhibit ion of ovulation initiated at least 3 months before the first dose of trial drug.
Oral. 
Intravaginal (eg, ring).
Transdermal. 
–Progestogen -only horm onal contracepti on associ ated wi th inhibit ion of ovulation 
initiated at least 3 months before the first dose of trial drug.
Oral. 
Injectable.
Implantable.
TAK -906
Study No. TAK -906-1003 Page 70of 70
Protocol Incorporating Amendment No. 01 25 May 2017
CONFIDENTIAL2.Since genotoxicit y/teratogeni city/embry otoxi city is unlikely  to be caused by  the 
investigat ional drug, additional effect ive methods of contraception (there may be a higher than 
1% failure rate) that may  be chosen by the female partner of a male subject are: 
Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams).
Progestogen only hormonal contraception, where inhibit ion of ovulat ion is not the primary 
mode of act ion. 
3.Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
4.Male subjects will be provided wit h information on highly effective/effect ive methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they  understand the requirements for avoidance of pregnancy and 
sperm  donat ion during the course of the trial.
5.Male subjects will receive continued guidance with respect to the avoidance of pregnancy and 
sperm  donat ion as part of the trial procedures. Such guidance should include a reminder of the 
following:
Contraceptive requirements of the trial.
Reasons for use of barrier methods (ie, condom) in males with pregnant partners.
Assessment of subject compliance through questions such as:
–Have you used the contraception consistent ly and correctly since the last visit ?
–Have you forgotten to use contraception since the last visit ?
    
 
  
 
  
 
ELECTRONIC SIGNATURES  
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
   
  
   
  
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 
090101d6805ff524Amendmend 01 to A Single-Sequence, Open-Label, 2-Period, Crossover Trial to Evaluate the Effect of the
Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult
Subjects
Clinical Pharmacology Approval 25-May-2017 13:38 UTC
Statistical Approval 25-May-2017 13:45 UTC
Clinical Approval 25-May-2017 23:37 UTC
PPD